NCT06745622 Long-term Safety and Tolerability of HSK39297 in Patients With Paroxysmal Nocturnal Hemoglobinuria
| NCT ID | NCT06745622 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Haisco Pharmaceutical Group Co., Ltd. |
| Condition | Paroxysmal Nocturnal Hemoglobinuria |
| Study Type | INTERVENTIONAL |
| Enrollment | 47 participants |
| Start Date | 2025-01-03 |
| Primary Completion | 2027-06 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
This is a multicenter, open-label study to evaluate the long-term safety, tolerability and efficacy of HSK39297. Adult patients with PNH who had previously received and completed HSK39297 study treatment will be included. Eligible subjects can maintain HSK39297 treatment until the end of the study.
Eligibility Criteria
Inclusion Criteria: 1. Patients With PNH who have previously received and completed HSK39297 treatment , and According to the researchers' judgment, the benefits of treatment outweigh the risks and may benefit from continued treatment with HSK39297; 2. Understand the study procedures and methods, voluntarily participate in this trial. Exclusion Criteria: 1. Hereditary or acquired complement deficiency; 2. Active primary or secondary immunodeficiency; 3. History of splenectomy, bone marrow/ hematopoietic stem cell or solid organ transplants; 4. History of recurrent invasive infections caused by encapsulated organisms( e.g. meningococcus or pneumococcus) or Mycobacterium tuberculosis; 5. History of serious comorbidities that have been determined to be unsuitable for participation in the study; 6. Pregnant or Lactating women.